Covina, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Viral Vectors and Plasmid DNA have become an important tool used for transferring genetic material into cells. Adenovirus, herpes simplex virus, lentivirus, ...
One strategy for improving selectivity of gene therapy is the use of a replication-activated adenovirus vector that mediates transgene expression specifically in tumor cells through homologous ...
The genetic medicine revolution is underway. Just 18 months ago, very few people in the general population had heard of mRNA vaccines; now, hundreds of millions globally have been vaccinated with one.
The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This ...
Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.
DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...
Ara Hacobian Ph.D. Head of Molecular Biology Ludwig Boltzmann Institute for Experimental and Clinical Traumatology David Hercher Ph.D. Master of Science Ludwig Boltzmann Institute for Experimental and ...
In the summer of 1812, French emperor Napoleon Bonaparte led about half a million soldiers to invade the Russian Empire. But ...
Touchlight scored another $125 million to boost manufacturing as the company looks to become a leading synthetic DNA producer for genetic medicines. The cell and gene therapy space has exploded in the ...
Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback